NCT00479700View on ClinicalTrials.gov

Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

May 31, 2006

Study Completion Date

July 31, 2006

Conditions
Alzheimer Disease
Interventions
DRUG

SAM-531

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00479700 - Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Subjects | Biotech Hunter | Biotech Hunter